• 1. Evolving better nanoparticles: Genetic algorithms for optimising cluster geometries
  Dalton Trans., 2003, 4193-4207
• 2. Examination of deposit in commercial diluted phosphoric acid
  Analyst, 1880,5, 146-147
• 3. Exceptional activity of sub-nm Pt clusters on CdS for photocatalytic hydrogen production: a combined experimental and first-principles study?
  Qiyuan Wu,Shangmin Xiong,Peichuan Shen,Shen Zhao,Alexander Orlov Catal. Sci. Technol., 2015,5, 2059-2064
• 4. Embedding cyclic nitrone in mesoporous silica particles for EPR spin trapping of superoxide and other radicals?
  Eric Besson,Stéphane Gastaldi,Emily Bloch,Selma Aslan,Hakim Karoui,Olivier Ouari,Micael Hardy Analyst, 2019,144, 4194-4203
• 5. Fast-Track to Research Data Management in Experimental Material Science-Setting the Ground for Research Group Level Materials Digitalization.
  LarsBanko,AlfredLudwig

• Solvents and Organic Chemicals Organic Compounds Organic acids and derivatives Carboxylic acids and derivatives Amino acids, peptides, and analogues Amino acids and derivatives

Recent Advances in the Study of (S)-2-Acetamido-5-ureidopentanoic acid (CAS: 33965-42-3)

The compound (S)-2-Acetamido-5-ureidopentanoic acid (CAS: 33965-42-3) has recently garnered significant attention in the field of chemical biology and medicinal chemistry due to its potential therapeutic applications. This brief aims to summarize the latest research findings related to this compound, focusing on its synthesis, biological activity, and potential clinical relevance.

Recent studies have highlighted the role of (S)-2-Acetamido-5-ureidopentanoic acid as a key intermediate in the biosynthesis of arginine and other biologically important molecules. Its structural similarity to naturally occurring amino acids makes it a promising candidate for drug development, particularly in the treatment of metabolic disorders and certain types of cancer. Researchers have employed advanced spectroscopic techniques, including NMR and mass spectrometry, to characterize its properties and interactions with biological targets.

One of the most notable findings is the compound's ability to modulate enzyme activity in pathways related to nitrogen metabolism. In vitro studies have demonstrated its inhibitory effects on specific enzymes, suggesting potential applications in targeting metabolic diseases. Furthermore, recent preclinical trials have shown that derivatives of (S)-2-Acetamido-5-ureidopentanoic acid exhibit enhanced bioavailability and reduced toxicity compared to earlier analogs.

The synthesis of (S)-2-Acetamido-5-ureidopentanoic acid has also seen advancements, with new methodologies offering higher yields and greater purity. Green chemistry approaches have been particularly successful, minimizing the use of hazardous reagents and reducing environmental impact. These developments are critical for scaling up production for potential clinical use.

In conclusion, (S)-2-Acetamido-5-ureidopentanoic acid represents a compound of significant interest in chemical biology and drug discovery. Ongoing research continues to uncover its multifaceted roles and potential therapeutic benefits. Future studies are expected to focus on optimizing its pharmacological properties and exploring its efficacy in vivo, paving the way for clinical trials.

• 56-85-9(L-Glutamine)
• 70-26-8((2S)-2,5-diaminopentanoic acid)
• 70-47-3(L-Asparagine)
• 1188-38-1(Carglumic Acid)
• 57-08-9(6-Acetamidohexanoic acid)
• 65-82-7(N-Acetyl-L-methionine)
• 40860-26-2(2-(carbamoylamino)pentanedioic Acid)
• 51-35-4(L-Hydroxyproline)
• 61-90-5(L-Leucine)
• 56-87-1(L-Lysine)